Research Topics
| Brian D PalmerSummaryAffiliation: University of Auckland Country: New Zealand Publications
| Collaborators
|
Detail Information
Publications
4-Phenylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione inhibitors of the checkpoint kinase Wee1. Structure-activity relationships for chromophore modification and phenyl ring substitutionBrian D Palmer
Auckland Cancer Society Research Centre, School of Medical Sciences, The University of Auckland, Private Bag 92019, Auckland 1020, New Zealand
J Med Chem 49:4896-911. 2006..These studies provide a basis for the design of active analogues of the pyrrolocarbazole lead with improved physical properties...- Structure-activity relationships for 2-anilino-6-phenylpyrido[2,3-d]pyrimidin-7(8H)-ones as inhibitors of the cellular checkpoint kinase Wee1Brian D Palmer
Auckland Cancer Society Research Centre, School of Medical Sciences, The University of Auckland, Private Bag 92019, Auckland, New Zealand
Bioorg Med Chem Lett 15:1931-5. 2005..Solubilizing substituents off the 2-anilino ring in many cases increased Wee1 activity, thus lowering this preference to about 10-fold. 5-Alkyl substituted analogs were generally Wee1 selective, but at the expense of absolute potency... 
Structure-activity relationships for amide-, carbamate-, and urea-linked analogues of the tuberculosis drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824)Adrian Blaser
Auckland Cancer Society Research Centre, School of Medical Sciences, The University of Auckland, Private Bag 92019, Auckland 1142, New Zealand
J Med Chem 55:312-26. 2012....- Synthesis and structure-activity studies of biphenyl analogues of the tuberculosis drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824)Brian D Palmer
Auckland Cancer Society Research Centre, School of Medical Sciences, The University of Auckland, Private Bag 92019, Auckland 1142, New Zealand
J Med Chem 53:282-94. 2010..In vivo activity correlated well with the stability of compounds to microsomal metabolism. Three compounds bearing combinations of lipophilic, electron-withdrawing groups achieved >200-fold higher efficacies than the parent drug... - Synthesis and structure-activity relationships of varied ether linker analogues of the antitubercular drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5h-imidazo[2,1-b][1,3]oxazine (PA-824)Andrew M Thompson
Auckland Cancer Society Research Centre, School of Medical Sciences, The University of Auckland, Private Bag 92019, Auckland 1142, New Zealand
J Med Chem 54:6563-85. 2011..One propynyloxy-linked compound displayed an 89-fold higher efficacy than the parent drug in the acute model, and it was slightly superior to antitubercular drug OPC-67683 in a chronic infection model... - Synthesis and structure-activity relationships of soluble 8-substituted 4-(2-chlorophenyl)-9-hydroxypyrrolo[3,4-c]carbazole-1,3(2H,6H)-diones as inhibitors of the Wee1 and Chk1 checkpoint kinasesJeff B Smaill
Auckland Cancer Society Research Centre, School of Medical Sciences, The University of Auckland, Private Bag 92019, Auckland 1142, New Zealand
Bioorg Med Chem Lett 18:929-33. 2008..Co-crystal structure studies confirm that the primary binding to the Wee1 enzyme is as described previously, with the C-8 side chains residing in an area of bulk tolerance... - Release of nitrite from the antitubercular nitroimidazole drug PA-824 and analogues upon one-electron reduction in protic, non-aqueous solventAndrej Maroz
Department of Chemistry, The University of Auckland, Private Bag 92019, Auckland, 1142, New Zealand
Org Biomol Chem 8:413-8. 2010..The described radiolytic quantification of nitrite release may have utility as a preliminary screening test for nitroaromatic candidate drugs against the disease... - Synthesis and structure-activity relationships of antitubercular 2-nitroimidazooxazines bearing heterocyclic side chainsHamish S Sutherland
Auckland Cancer Society Research Centre, School of Medical Sciences, The University of Auckland, Private Bag 92019, Auckland 1142, New Zealand
J Med Chem 53:855-66. 2010..tb than predicted by their lipophilicities. Two pyrazole analogues were >10-fold more efficacious than the parent drug in a mouse model of acute M. tb infection, and one displayed a 2-fold higher solubility... - Synthesis and structure-activity relationships of N-6 substituted analogues of 9-hydroxy-4-phenylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-diones as inhibitors of Wee1 and Chk1 checkpoint kinasesJeff B Smaill
Auckland Cancer Society Research Centre, School of Medical Sciences, The University of Auckland, Private Bag 92019, Auckland 1020, New Zealand
Eur J Med Chem 43:1276-96. 2008..HT-29 cells treated with doxorubicin and then target compounds demonstrate an active Cdc2/cyclin B complex, inhibition of the doxorubicin-induced phosphorylation of tyrosine 15 of Cdc2 and abrogation of the G2 checkpoint... 
Labeling of oxidizable proteins with a photoactivatable analog of the antitumor agent DMXAA: evidence for redox signaling in its mode of actionRomy Brauer
Auckland Cancer Society Research Centre, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand
Neoplasia 12:755-65. 2010..The results from these lines of study all suggest that redox signaling plays a central role in cytokine induction by DMXAA...- Synthesis, reduction potentials, and antitubercular activity of ring A/B analogues of the bioreductive drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824)Andrew M Thompson
Auckland Cancer Society Research Centre, School of Medical Sciences and Department of Chemistry, The University of Auckland, Private Bag 92019, Auckland 1142, New Zealand
J Med Chem 52:637-45. 2009.... - Effect of 3-fluorothalidomide and 3-methylthalidomide enantiomers on tumor necrosis factor production and antitumor responses to the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA)Francisco Chung
Auckland Cancer Society Research Center, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand
Oncol Res 14:75-82. 2003..We conclude that there is no advantage in using the nonracemizable thalidomide analogues to improve the antitumor activity of DMXAA... - Synthesis and biological activity of azido analogues of 5,6-dimethylxanthenone-4-acetic acid for use in photoaffinity labelingBrian D Palmer
Auckland Cancer Society Research Centre, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand
J Med Chem 50:3757-64. 2007..The azido compounds 2 and 3 exhibit all the requirements for use in photoaffinity labeling of potential receptor(s) for 1... - The nitroimidazooxazines (PA-824 and analogs): structure-activity relationship and mechanistic studiesWilliam A Denny
Auckland Cancer Society Research Centre, School of Medical Sciences, The University of Auckland, Private Bag 92019, Auckland 1142, New Zealand
Future Med Chem 2:1295-304. 2010..Bioreductive drugs such as PA-824 hold the promise of shorter treatment regimens... - Intermediates in the reduction of the antituberculosis drug PA-824, (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine, in aqueous solutionRobert F Anderson
Department of Chemistry, The University of Auckland, Private Bag 92019, Auckland 1142, New Zealand
Org Biomol Chem 6:1973-80. 2008..The unique properties of the intermediates formed on the reduction of PA-824 need to be considered as playing a possible role in its bactericidal action... - Uptake of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and activation of NF-kappaB in human tumor cell linesSee Tarn Woon
Auckland Cancer Society Research Centre, Faculty of Medical and Health Sciences, The University of Auckland, New Zealand
Oncol Res 13:95-101. 2002..The observed activation of NF-kappaB in some lines suggests that the effects of DMXAA on tumor cells, as well as host cells, must be considered in understanding its antitumoraction... - Effect of nitroreduction on the alkylating reactivity and cytotoxicity of the 2,4-dinitrobenzamide-5-aziridine CB 1954 and the corresponding nitrogen mustard SN 23862: distinct mechanisms of bioreductive activationNuala A Helsby
Auckland Cancer Society Research Centre, The University of Auckland, Private Bag 92019, Auckland, New Zealand
Chem Res Toxicol 16:469-78. 2003..The single-step bioactivation of 6, to amino or hydroxylamine metabolites with similar potency to 4, is a potential advantage in the use of dinitrobenzamide mustards as prodrugs for activation by nitroreductases... - Thalidomide pharmacokinetics and metabolite formation in mice, rabbits, and multiple myeloma patientsFrancisco Chung
Auckland Cancer Society Research Centre, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand
Clin Cancer Res 10:5949-56. 2004..We suggest that the interspecies differences in biological effects of thalidomide may be attributable, at least in part, to the differences in its metabolism and hence pharmacokinetics... - Metabolism of thalidomide in liver microsomes of mice, rabbits, and humansJun Lu
The Auckland Cancer Society Research Center, Faculty of Medical and Health Sciences, The University of Auckland, Private Bag 92019, Auckland, New Zealand
J Pharmacol Exp Ther 310:571-7. 2004..The very low rate of in vitro and in vivo hydroxylation in humans strongly suggests that thalidomide hydroxylation is not a requirement for clinical anticancer activity... - Aziridinyldinitrobenzamides: synthesis and structure-activity relationships for activation by E. coli nitroreductaseNuala A Helsby
Auckland Cancer Society Research Centre, School of Medical Sciences, Faculty of Medical and Health Sciences, The University of Auckland, Private Bag 92019, Auckland, New Zealand
J Med Chem 47:3295-307. 2004..The results suggest there may be advantages with carefully selected analogues of CB 1954; the weaker bystander effect of its diol derivative may be an advantage in the selective cell ablation of NTR-tagged cells in normal tissues... - Thalidomide metabolites in mice and patients with multiple myelomaJun Lu
Auckland Cancer Society Research Centre, Faculty of Medical and Health Sciences, The University of Auckland, New Zealand
Clin Cancer Res 9:1680-8. 2003..We suggest that thalidomide may act directly, down-regulating growth factors essential for multiple myeloma growth... - Potentiation of the antitumour effect of cyclophosphamide in mice by thalidomideQi Ding
Auckland Cancer Society Research Centre, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand
Cancer Chemother Pharmacol 50:186-92. 2002..Investigation of the reason for this effect revealed thalidomide to possess the novel property of dramatically decreasing the clearance of cyclophosphamide and its metabolites...